does medicare cover glp-1 Bridge Program Explained: Medications for Weight Loss CMS has announced important updates

GLP-1 medications interact with certain drugs, supplements, and substances that may reduce efficacy or increase side effects

Tirzepatide, a novel GLP-1/GIP dual receptor agonist, shows significant advantages in glycemic management and weight control

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

Called Foundayo, the tablet becomes the second one to receive FDAs green light after Novo Nordisks Wegovy

However, there was progress in the UK where the government announced Scotland CardioMetabolic Impact Study (SCoMIS) , a pioneering Real-World study, which will provide Wegovy to between 3,000-5,000 people living with Obesity in Scotlands poorest areas free of charge during a three year study [11] Despite FDA phasing out enforcement discretion that allowed GLP-1 compounding during shortages - and setting May 2025 deadlines for compounding to cease - compounding has continued beyond this deadline [12]